Celldex Q3 net loss $67M; barzolvolimab Phase 2 data positive in urticarias

Celldex Therapeutics, Inc.

2025-Q3 EPS reported -$2.67 revenue$1,424,000

Net loss of $67.0M ($1.01/share) vs $42.1M in Q3 2024; cash use $48.6M in operations.
Cash & securities $583.2M as of Sep 30, 2025; runway through 2027.
Phase 2 barzolvolimab met endpoints in CSU, ColdU, and SD; 71% complete response at 52 weeks (CSU).
Phase 1 CDX-622 (bispecific SCF & TSLP) well tolerated; Part 2 enrollment ongoing.
Teri Lawver hired as SVP, Chief Commercial Officer; Phase 3 ColdU/SD study to start Dec 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.